Immune cells decide how to respond, not only whether to. Thymosin alpha-1 is studied for its part in that decision.
Thymosin Alpha-1 · Thymic immune-signalling peptide
Immune cells do not simply attack; they receive signals that shape what kind of response to mount. The thymus, the organ where T cells mature, produces several such signals. Thymosin alpha-1 is one of them, and researchers study how it changes the behaviour of dendritic cells and T cells. Evidence comes from cell and mouse work and from clinical trials of the synthetic form, thymalfasin, in chronic hepatitis B.
Thymosin alpha-1 is a 28-amino-acid peptide first isolated from calf thymus by Goldstein and colleagues in 1977, as one of the active components of a thymic extract called fraction 5 (Goldstein et al. 1977). The synthetic form is called thymalfasin.
Its research history sits in immunology rather than tissue repair, which distinguishes it from most compounds in this category. The mechanism studied is immune modulation: changing how immune cells respond, not making immunity stronger. In cell and mouse experiments the peptide acts on dendritic cells, the cells that present foreign material to T cells and set the direction of the response, through Toll-like receptors, a family of sensors that detect microbial patterns. That signalling shifts dendritic cells towards producing interleukin-12 and steering T helper cells down a Th1 path, the branch associated with responses to intracellular pathogens (Romani et al. 2004).
Mechanistic work has used mouse dendritic cells exposed to Aspergillus fumigatus and mice given haematopoietic transplants, measuring dendritic-cell maturation, interleukin-12 output and survival after fungal challenge (Romani et al. 2004). These are cell and animal findings about signalling, not evidence of an effect in healthy people.
The main human literature concerns thymalfasin in chronic hepatitis B. A randomised controlled trial in 98 patients compared 26 or 52 weeks of subcutaneous thymalfasin with no treatment and measured virological response and liver histology; complete virological response was higher in the treated groups at 18 months, although not at the end of therapy (Chien et al. 1998). Combination trials with interferon in hepatitis B and C and in some cancers followed (Garaci et al. 2007). Reviews also describe its study as a vaccine adjunct, in sepsis and, during the COVID-19 period, in small trials (Dominari et al. 2020).
Thymalfasin has been used as a registered medicine in some countries for chronic hepatitis B. This note did not verify any individual national registration against a regulator record, so no count of jurisdictions is given here. It is not FDA-approved and is not an approved medicine in Australia.
The human evidence is condition-specific: patients with chronic hepatitis B or particular cancers, treated with pharmaceutical thymalfasin, often alongside interferon. Those results do not show what the peptide does in a person without those conditions, and they are not evidence of general immune support.
The Toll-like receptor mechanism is drawn from mouse and cell work. Whether the same signalling changes occur, or matter, in humans at research-relevant exposures is not established. Older trials predate current antiviral standards, which limits how their results read today.
Thymosin alpha-1 is not an approved medicine in Australia. The synthetic form, thymalfasin (marketed as Zadaxin), is not approved by the US FDA; registrations reported in other countries for chronic hepatitis B were not individually verified against a regulator record for this note.
Sources and status checked 2026-09-22
Thymosin Alpha-1 — sizes and pricing